JP2025118729A5 - - Google Patents
Info
- Publication number
- JP2025118729A5 JP2025118729A5 JP2025075148A JP2025075148A JP2025118729A5 JP 2025118729 A5 JP2025118729 A5 JP 2025118729A5 JP 2025075148 A JP2025075148 A JP 2025075148A JP 2025075148 A JP2025075148 A JP 2025075148A JP 2025118729 A5 JP2025118729 A5 JP 2025118729A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- cancer
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263323607P | 2022-03-25 | 2022-03-25 | |
| US63/323,607 | 2022-03-25 | ||
| US202263406906P | 2022-09-15 | 2022-09-15 | |
| US63/406,906 | 2022-09-15 | ||
| US202263386404P | 2022-12-07 | 2022-12-07 | |
| US63/386,404 | 2022-12-07 | ||
| JP2024556680A JP7676677B2 (ja) | 2022-03-25 | 2023-03-24 | Ｋｒａｓ阻害剤 |
| PCT/US2023/016257 WO2023183585A1 (en) | 2022-03-25 | 2023-03-24 | Kras inhibitors |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024556680A Division JP7676677B2 (ja) | 2022-03-25 | 2023-03-24 | Ｋｒａｓ阻害剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025118729A JP2025118729A (ja) | 2025-08-13 |
| JP2025118729A5 true JP2025118729A5 (https=) | 2026-04-06 |
Family
ID=86331239
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024556680A Active JP7676677B2 (ja) | 2022-03-25 | 2023-03-24 | Ｋｒａｓ阻害剤 |
| JP2025075148A Pending JP2025118729A (ja) | 2022-03-25 | 2025-04-30 | Ｋｒａｓ阻害剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024556680A Active JP7676677B2 (ja) | 2022-03-25 | 2023-03-24 | Ｋｒａｓ阻害剤 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US12351591B2 (https=) |
| EP (1) | EP4499233A1 (https=) |
| JP (2) | JP7676677B2 (https=) |
| KR (2) | KR102847563B1 (https=) |
| CN (1) | CN119095853A (https=) |
| AU (1) | AU2023241055A1 (https=) |
| CA (1) | CA3246810A1 (https=) |
| CL (1) | CL2024002874A1 (https=) |
| CO (1) | CO2024012604A2 (https=) |
| DO (1) | DOP2024000186A (https=) |
| IL (1) | IL315782A (https=) |
| JO (1) | JOP20240210A1 (https=) |
| MX (1) | MX2024011631A (https=) |
| PE (1) | PE20251071A1 (https=) |
| TW (2) | TWI852436B (https=) |
| WO (1) | WO2023183585A1 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024112654A1 (en) | 2022-11-21 | 2024-05-30 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| WO2024206747A1 (en) * | 2023-03-30 | 2024-10-03 | Eli Lilly And Company | Kras inhibitors |
| EP4687905A1 (en) | 2023-03-30 | 2026-02-11 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| EP4688792A1 (en) * | 2023-03-31 | 2026-02-11 | Eli Lilly and Company | Kras inhibitors |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| AU2024323424A1 (en) | 2023-08-17 | 2026-03-05 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| AU2024337913A1 (en) | 2023-09-08 | 2026-03-26 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| TW202528315A (zh) | 2023-09-21 | 2025-07-16 | 美商樹線生物科學公司 | 螺環二氫哌喃并吡啶ＫＲａｓ抑制劑 |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025092798A1 (zh) * | 2023-10-30 | 2025-05-08 | 江苏恒瑞医药股份有限公司 | 稠合杂芳基类化合物、其制备方法及其在医药上的应用 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547457A (zh) * | 2024-04-08 | 2025-12-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 二氫呋喃并[3,4-f]喹唑啉類化合物、其製備方法及其在醫藥上的應用 |
| WO2025214344A1 (zh) * | 2024-04-09 | 2025-10-16 | 上海和誉生物医药科技有限公司 | 一种kras抑制剂及其在药学上的应用 |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025245127A1 (en) | 2024-05-21 | 2025-11-27 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026035945A1 (en) | 2024-08-07 | 2026-02-12 | Tesseract Medicines Us, Llc | Covalent-induced drug conjugates targeting kras and comprising a topoisomerase payload |
| WO2026035947A1 (en) | 2024-08-07 | 2026-02-12 | Tesseract Medicines Us, Llc | Kras-targeting covalent-induced drug conjugates comprising a topoisomerase payload |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026059955A1 (en) * | 2024-09-11 | 2026-03-19 | Eli Lilly And Company | (3-((6-(2-amino-benzo[d]thiazol-4-yl)-3-(pyrrolidin-1-yl)-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)amino)- piperidin-2-one derivatives as kras inhibitors for the treatment of cancer |
| WO2026064527A1 (en) | 2024-09-19 | 2026-03-26 | Tesseract Medicines Us, Llc | Kras-targeting covalent-induced drug conjugates comprising a tubulin inhibitor payload |
| WO2026064520A1 (en) | 2024-09-19 | 2026-03-26 | Tesseract Medicines Us, Llc | Covalent-induced drug conjugates targeting kras and comprising a tubulin inhibitor payload |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| US12600733B2 (en) * | 2024-10-01 | 2026-04-14 | Eli Lilly And Company | KRAS inhibitors |
| WO2026075942A1 (en) * | 2024-10-01 | 2026-04-09 | Eli Lilly And Company | Kras inhibitors |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10844051B2 (en) | 2015-07-22 | 2020-11-24 | The Royal Institution For The Advancement Of Learning/Mcgill University | Substituted oxazoles for the treatment of cancer |
| HRP20230377T1 (hr) | 2017-11-15 | 2023-06-23 | Mirati Therapeutics, Inc. | Inhibitori mutacije kras g12c |
| TW202033518A (zh) * | 2018-10-15 | 2020-09-16 | 美商美國禮來大藥廠 | Kras g12c 抑制劑 |
| WO2020146613A1 (en) | 2019-01-10 | 2020-07-16 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| WO2021041671A1 (en) | 2019-08-29 | 2021-03-04 | Mirati Therapeutics, Inc. | Kras g12d inhibitors |
| ES2929700T3 (es) | 2019-12-11 | 2022-12-01 | Lilly Co Eli | Inhibidores de KRas g12c |
| EP4161934A1 (en) * | 2020-06-04 | 2023-04-12 | Antengene Discovery Limited | Inhibitors of kras g12c protein and uses thereof |
| CN113880827B (zh) * | 2020-07-03 | 2024-10-01 | 苏州闻天医药科技有限公司 | 一种用于抑制krasg12c突变蛋白的化合物及其制备方法和用途 |
| CN116368130A (zh) * | 2020-08-28 | 2023-06-30 | 金橘生物科技公司 | 杂环化合物及其用途 |
| US20240166660A1 (en) | 2021-01-15 | 2024-05-23 | Beigene Switzerland Gmbh | Kras g12c inhibitors |
| WO2022184178A1 (en) | 2021-03-05 | 2022-09-09 | Jacobio Pharmaceuticals Co., Ltd. | Kras g12d inhibitors |
| CA3210383A1 (en) * | 2021-03-12 | 2022-09-15 | Bristol-Myers Squibb Company | Kras inhibitors |
| CN117500799A (zh) | 2021-06-09 | 2024-02-02 | 伊莱利利公司 | 作为kras g12d抑制剂的取代的稠合吖嗪 |
| WO2023061294A1 (zh) | 2021-10-13 | 2023-04-20 | 再鼎医药(上海)有限公司 | 含氮杂环类衍生物调节剂、其制备方法及应用 |
-
2023
- 2023-03-24 JP JP2024556680A patent/JP7676677B2/ja active Active
- 2023-03-24 PE PE2024001867A patent/PE20251071A1/es unknown
- 2023-03-24 AU AU2023241055A patent/AU2023241055A1/en active Pending
- 2023-03-24 KR KR1020247035268A patent/KR102847563B1/ko active Active
- 2023-03-24 EP EP23723097.4A patent/EP4499233A1/en active Pending
- 2023-03-24 WO PCT/US2023/016257 patent/WO2023183585A1/en not_active Ceased
- 2023-03-24 US US18/189,713 patent/US12351591B2/en active Active
- 2023-03-24 KR KR1020257020079A patent/KR20250093430A/ko active Pending
- 2023-03-24 IL IL315782A patent/IL315782A/en unknown
- 2023-03-24 CA CA3246810A patent/CA3246810A1/en active Pending
- 2023-03-24 CN CN202380030401.9A patent/CN119095853A/zh active Pending
- 2023-03-24 MX MX2024011631A patent/MX2024011631A/es unknown
- 2023-03-25 TW TW112111395A patent/TWI852436B/zh active
- 2023-03-25 TW TW113108193A patent/TW202438502A/zh unknown
-
2024
- 2024-09-17 CO CONC2024/0012604A patent/CO2024012604A2/es unknown
- 2024-09-20 DO DO2024000186A patent/DOP2024000186A/es unknown
- 2024-09-25 CL CL2024002874A patent/CL2024002874A1/es unknown
- 2024-09-26 JO JOJO/P/2024/0210A patent/JOP20240210A1/ar unknown
-
2025
- 2025-04-30 JP JP2025075148A patent/JP2025118729A/ja active Pending
- 2025-05-29 US US19/222,746 patent/US20250289830A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025118729A5 (https=) | ||
| IL315782A (en) | Kras inhibitors | |
| JP7735368B2 (ja) | Ｒｉｐ１阻害剤化合物並びにそれを製造及び使用するための方法 | |
| JP7348906B2 (ja) | フェロトーシス誘導活性を有する化合物およびそれらの使用方法 | |
| EP3250567B1 (en) | 4h-pyrrolo[3,2-c]pyridin-4-one derivatives | |
| EP4097095A1 (en) | Ras inhibitors and methods of using the same | |
| CN116531380B (zh) | 用于治疗癌症的2-杂芳基-3-氧代-2,3-二氢哒嗪-4-甲酰胺 | |
| JP2024520791A (ja) | 化合物 | |
| CN108366994B (zh) | 新型Jak1选择性抑制剂及其用途 | |
| KR102122244B1 (ko) | 설파모일-아릴아미드 및 b형 간염 치료제로서의 그 용도 | |
| CN111989332A (zh) | 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用 | |
| CN114072400A (zh) | 极光激酶抑制剂及其用途 | |
| HK1212345A1 (en) | 4-substituted pyrrolo- and pyrazolo-diazepines | |
| CN113795307A (zh) | 吡啶并嘧啶基化合物及其使用方法 | |
| CN102480957A (zh) | 治疗癌症及非肿瘤病症的方法 | |
| WO2024047135A1 (en) | Substituted heterocycles as ras inhibitors | |
| EP4234548A1 (en) | Substituted benzo or pyridopyrimidine amine inhibitor, preparation method therefor, and application thereof | |
| CN104650070A (zh) | 二氢嘧啶类化合物及其在药物中的应用 | |
| KR102926889B1 (ko) | Cdk8/19 저해제 | |
| JP2023526443A (ja) | Ｒｏｎ変異が関与する非小細胞肺がんの予防又は治療用医薬組成物及びその使用方法 | |
| JP7733274B1 (ja) | Ｇ１２ｄ変異ｋｒａｓ阻害活性を有する二官能性化合物を含む抗がん剤の組合せ | |
| WO2018092916A1 (ja) | 含窒素多環式ヘテロ環誘導体 | |
| IL293861A (en) | Combination of an ahr-inhibitor and an pd1-inhibitor antibody and its use in the treatment of cancer | |
| HK40056588A (en) | Pyrido-pyrimidinyl compounds and methods of use | |
| CN115038700A (zh) | 偕二取代的杂环化合物及其作为idh抑制剂的用途 |